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ABSTRACT 
Neuroinflammation is associated with neurodegenerative disease. PET (positron emission 
tomography) radioligands targeting the 18 kDa translocator protein (TSPO) has been used 
as in vivo markers of neuroinflammation, but there is an urgent need for novel probes with 
improved signal-to-noise ratio. Flutriciclamide (18F-GE180) is a recently developed third 
generation TSPO ligand. In this first study, we evaluated the optimum scan duration and 
kinetic modelling strategies for 18F-GE180 PET in (older) healthy controls (HC).  
Methods: Ten HC, six TSPO high affinity binders (HABs) and four mixed affinity binders 
(MABs), were recruited. All subjects had detailed neuropsychological tests, MRI and a 210 
min 18F-GE180 dynamic PET/CT scan using metabolite corrected arterial plasma input 
function. We evaluated five different kinetic models: irreversible and reversible two-tissue 
compartment models, a reversible one-tissue model and two models with an extra 
irreversible vascular compartment. The optimum scan length was investigated based on 
210 min scan data. The feasibility of generating parametric maps was also investigated 
using graphical analysis.  
Results: 18F-GE180 concentration was higher in plasma than in whole blood during the 
entire scan duration. Using the kinetic model, the volume of distribution (VT) was 0.17 in 
HABs and 0.12 in MABs. The model that best represented brain 18F-GE180 kinetics across 
regions was the reversible two-tissue compartment model (2TCM4k) and 90 min resulted 
as the optimum scan length required to obtain stable estimates. Logan graphical analysis 
with arterial input function gave a VT highly consistent with VT in kinetic model, which 
could be used for voxel-wise analysis.  
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Conclusion: We report for the first time the kinetic properties of the novel third generation 
TSPO PET ligand, 18F-GE180, in humans: 2TCM4k is the optimal method to quantify the 
brain uptake, 90 min is the optimal scan length and Logan approach could be used to 
generate parametric maps. While these control subjects have shown relatively low VT, the 
methodology presented here forms the basis for quantification for future PET studies using 
18F-GE180 in different pathologies. 
 
Key words: GE180, Flutriciclamide, Kinetic Model, Logan analysis, PET. 
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INTRODUCTION 
Microglia plays a crucial role as the first line of defense when neuronal damage occurs. 
Under normal conditions microglial cells are in a state of surveillance with elongated 
processes. During injury or neurodegenerative processes, microglial cells become 
activated; the activated state is mirrored by up regulation of translocator protein (TSPO) 
(1, 2). Positron emission tomography (PET) with TSPO specific ligands provide an in vivo 
technique to detect microglial activation (3). 
 
11C-(R)-PK11195 PET has been used for more than two decades. However, due to low 
signal-to-background ratio and short half-life (20 min), second generation TSPO markers 
have been developed. These include 18F-FEPPA, 18F-FEDAA1106, 11C-vinpocetine, 11C-
DAC, 11C-DAA1106, 11C-N1-methyl-2-phenylindol-3-ylglyoxylamide , 11C-CLINME, 
11C-DPA-713, 18F-DPA-714, 18F-PBR06 and 11C-PBR28 (4). However, the results 
obtained by second generation radioligands in pre-clinical models have not been 
consistently reproduced in humans (5). Their quantification in humans suffers from three 
confounding factors (6). The first factor is genetic: a single nucleotide polymorphism in 
the TSPO gene (rs6971) leads to an amino-acid substitution (A147T) and reduced binding 
affinity. The second factor is the disproportion between the high signal from the TSPO in 
the endothelial cells of the blood-brain barrier (BBB) and venous sinuses and the signal 
from the tissue, requiring appropriate kinetic correction (7). The third factor is the difficulty 
in obtaining accurate estimates of free plasma concentrations for proper quantification. 
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Flutriciclamide (18F-GE180) has been identified as a promising TSPO tracer in preclinical 
models of stroke and lipopolysaccharide (LPS)-induced central nervous system 
inflammation (8, 9). Here we report the results of a study evaluating 18F-GE180 PET in 
healthy human brains. We have investigated: 1) blood tracer concentrations 2) brain uptake 
3) quantification of binding via tracer kinetic modeling 4) optimal scan length and 5) 
feasibility of generating parametric maps.  
MATERIALS AND METHODS 
Fifteen HC aged 50-85 were recruited. Subjects who were high (HABs=6) or mixed affinity 
binders (MABs=4) proceeded to MRI and PET scans, while low affinity binders (LABs=5) 
were excluded. Details of recruitment, demography, and MRI acquisition in 
Supplementary file 1.  
GE180 PET  
18F-GE180 was manufactured on the GE FASTlab (10). All subjects received 185 MBq 
18F-GE180 by bolus intravenous injection (in 20 seconds) immediately before the PET 
scan. The scan was acquired using a Siemens Biograph 6 PET/CT scanner (11). An initial 
CT was acquired for patient position and for attenuation correction of PET images. The 
tracer was then injected and dynamic emission PET images were acquired over 210 
minutes using predetermined time frames: 6x15s, 3x60s, 5x120s, 5x300s, and 14x600s. 
Images were corrected for attenuation, random and scattered emissions based on the 3D 
ordinary Poisson ordered-subset expectation maximization algorithm. Reconstruction of 
PET was carried out using filtered back projection.   
Blood data 
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Arterial whole blood activity was continuously monitored for the first 15 min of the PET 
scan using the Allogg automated blood sampling system (ABSS) with real-time online 
blood sampling. Ten discrete arterial blood samples were taken at 5, 10, 15, 30, 60, 90, 
120, 150, 180 and 210 min of the PET scan. The activity concentration was measured in 
both whole blood and plasma by a well counter and was used to generate a plasma:blood 
ratio curve. Applying the plasma:blood ratio model to the first 15 min of continuous whole 
blood data, the time course of activity in the plasma can be estimated with a sigmoidal 
fitting.  
 
Metabolites of 18F-GE180 were measured by HPLC (High-performance liquid 
chromatography) analysis (10) using discrete blood samples. A two-exponential linear 
model was used to describe the parent fraction of 18F-GE180, which was applied to the 
plasma to generate the parent plasma input function. Standardized uptake value (SUV) was 
applied to both total blood and parent plasma with the formula:  
ܷܸܵ = 18F − GE180 ܽܿݐ݅ݒ݅ݐݕ ܿ݋݊ܿ݁݊ݐݎܽݐ݅݋݊(݇ܤݍ/݈݉)18F − GE180  ݆݅݊݁ܿݐ݁݀ ݀݋ݏ݁(ܯܤݍ)
ܤ݋݀ݕ ܹ݁݅݃ℎݐ(݇݃)൘
 
Finally, the time delay (the arrival of the 18F-GE180 bolus at the peripheral sampling site) 
was determined using MICK.exe (Quantitative software for the PET analysis) and were 
performed based on MATLAB®2014 (The MathWorks, USA) on Windows platform.  
Region of interest analysis 
Each subject underwent two 90 min PET scans with a 20 min break in between; the 
realignment approach was necessary to re-align the second scan to the first scan.  Head 
motions were corrected using the frame-by-frame realignment tools in Statistical 
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Parametric Mapping (SPM). Based on the visual resolution, the 8th frame (185–245s) was 
selected as the reference frame for each time frame realigning to. An individualized object 
map in PET space was created with the following procedure: 1) MRI was co-registered to 
the PET add image (60 – 90 min); 2) a binary grey and white matter mask was created via 
segmentation; 3) the probabilistic ROI atlas (12) in MNI space was transformed into native 
PET space; 4) we applied the binary mask to the ROI atlas to generate individual ROIs. 
Regional time activity curves (TACs) were generated by sampling the dynamic PET 
images with the individual ROIs for the following merging regions: frontal, temporal, 
parietal, occipital lobes and whole brain. Additional sampling of posterior cingulate, 
thalamus, brainstem, whole medial temporal lobe, hippocampus, and cerebellum was 
performed. The parahippocampus, anterior cingulate and amygdala were sampled as 
additional ROIs using Analyze 11.0. The SUV TAC was generated for each 18F-GE180 
dynamic PET by dividing the ratio of 18F-GE180 injected dose over body weight. 
Kinetic modeling 
Parent plasma input function and dynamic PET were used to investigate the best kinetic 
model to compute 18F-GE180 total volume of distribution (VT) from TACs using MICK 
software (Modeling-Input-function-Compartmental-Kinetics) and MATLAB. We 
evaluated five different kinetic models (Supplementary file 2). 18F-GE180 tissue data were 
investigated with the reversible one-tissue 2k (1TCM2k), the two-tissue 4k (2TCM4k) 
model and the irreversible two-tissue 3k (1TCM3k), where k implies the rate constant for 
tracer for different kinetic compartments. As tracer binds to BBB endothelial cells, 
endothelia could have significant impact on kinetic modeling (13, 14); therefore we also 
considered one-tissue with extra vascular component (1TCM2k-1k) and two-tissue with 
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extra vascular component (2TCM4k-1k). The additional component describes the trapping 
of the tracer by the endothelial cells of blood vessels. Akaike Information Criterion (AIC) 
(15) is a statistical measure to estimate the quality of fit of the predicted model against the 
actual data using different statistical models. In simple terms, the AIC values indicate the 
information lost when a candidate model is applied to estimate the real data,  and  the model 
with the smallest AIC value should be selected as the preferred model, as it indicates the 
best fit (16). In order to select the best model to quantify the tracer, AIC is calculated using 
the following formula: 
AIC = n ∗ ln(wrss) + 2m 
where m denotes number of parameters, n equals the sum of degrees of freedom and 
number of parameters, wrss denotes weighted residual sum of squares (17). The AIC 
fraction was also calculated by measuring the frequency of AIC preferences for each model 
across all subjects (18). AIC was calculated for the following brain regions: frontal, 
temporal, parietal, occipital lobes, whole brain, posterior-cingulate, thalamus, striatum, 
brainstem, medial-temporal-lobe, hippocampus and cerebellum. Coefficient of variation 
(CV) was measured to assess dispersion and precision of parameters. We also evaluated 
the separation in average binding between high and mixed affinity binder classes. 
Graphical analysis  
Graphical analysis was applied to investigate the feasibility of generating parametric maps 
of 18F-GE180. Logan or Patlak plot were involved based on the nature of the tracer 
(reversible or irreversible). Initially we calculated the optimal threshold time by linear fit 
the tissue:plasma ratio against the time. 18F-GE180 parametric maps were generated with 
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the parent plasma input function and dynamic PET images using MICK parametric map 
software on MATLAB. 
Optimisation of scan length 
The optimum scan duration was evaluated measuring the percentage change of k (rate 
constants) and VT, along with their CV at different time durations, calculated at 60 min, 75 
min, 90 min, 150 min, 180 min, and 210 min. k3 and k4 indicate the rate constant of 18F-
GE180 in and out of the specific-bound compartment, while the k3/k4 ratio represents the 
specific binding of the tracer. Thus, the k3/k4 ratio was measured to investigate whether 
the binding potential of 18F-GE180 was affected when the scanning time was reduced. 
Statistical analysis 
Statistical analysis of group-wise differences between different kinetic models, different 
scan durations and ROI VT in different genetic groups was calculated in SPSS for Windows 
version 22 (SPSS, Chicago, Illinois, USA). A p value of <0.05 was regarded as a statistical 
difference. The Pearson correlation was applied to measure the linear correlation between 
two groups of variables using SPSS22. Repeated measures ANOVA (analysis of variance) 
was applied to detect any overall differences between repeated measurements.  
 
RESULTS 
Parent plasma input 
Consistent with the preclinical work (8), the radiochromatogram revealed three identifiable 
radiolabeled metabolites and a parent 18F-GE180 in human plasma (Fig.1A). The parent 
fraction of 18F-GE180 gradually reduced from 90% to 60%. There was no group difference 
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between HABs and MABs in metabolic rates and plasma:blood curve (Fig.1B and Fig.1C). 
The 18F-GE180 activity concentration in plasma was 1.6-fold higher than in whole blood. 
No difference in parent plasma input function between HABs and MABs was found 
(Fig.1D). 
Dynamic PET image TAC 
As tracer concentrations are correlated with injected dose and individual weight, we 
measured SUV TAC values at each time frame. The tracer activity concentration in the 
brain peaked at 125 seconds with SUV at 1.5 and then quickly washed out and reached a 
plateau around 40 min. As a group, SUVs were significantly higher in HABs than MABs 
in temporal lobe (p=0.0001), thalamus (p=0.0001) and striatum (p=0.0002) (Fig.2). The 
venous sinuses showed consistently highest tracer activity throughout the scan, while grey 
matter showed around 30% higher activity concentration than white matter.  
Kinetic modeling 
Among five kinetic models, two-tissue reversible model (2TCM4k) showed the lowest AIC 
value in frontal (-59.6±5.4), temporal (-46.4±4.5), parietal (-58.6±5.4) and occipital lobes 
(-54.3±5.1) as a group (Fig 3A). 2TCM4k model also showed the highest AIC fraction (Fig 
3B). While the 2TCM3k irreversible model demonstrated closer AIC values (less than 10% 
difference compared to 2TCM4k model), the ki (net influx constant), demonstrating the 
overall net rate of tracer uptake into tissue in 2TCM3k model, showed poor precision with 
high coefficient of variation (CV=104±85%) while VT in reversible 2TCM4k had a CV of 
21±13%. Based on the model curve fitting, 2TCM4k provided a good fit to 18F-GE180 
activity, supported by smallest weighted residual sum square and more random in 
residual’s sequence (similar number of residuals above or below the model curve) using 
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Wald-Wolfowitz test. In summary, the 2TCM4k is the preferred method of analysis of 18F-
GE180 PET. Supplementary file 3 details rate constants (K1, k2, k3 and k4), blood volume 
and VT applying the 2TCM4k model in HABs and MABs which showed good precision of 
parameter estimation.  
Volume of distribution 
As a group, ten HC had low mean VT in whole brain, but slightly higher in temporal lobe, 
occipital lobe and thalamus (Fig.4). Thalamus, parahippocampus, and cerebellum showed 
significantly higher mean VT values in HABs compared with MABs (Table 1).  
Scan length 
210 min data was excluded as variance was very high towards the end of the scan. Repeated 
ANOVA did not show difference in the absolute VT when reducing the scan duration. In 
this study, the group mean of k3/k4 ratio (HAB=0.52 and MAB=0.34) was calculated to 
evaluate the results among different scan lengths, showing no differences with scan length 
reduction from 180 min to 90 min. When the scan length was further reduced to 75 min, 
the k3/k4 ratio remained the same as with the 90 min data, but four individual subjects 
showed a 14% reduction in k3/k4 ratio. Compared to 90 min scans, 60 min scans showed 
a 51% reduction in k3/k4 ratio as a group. These data suggest that for this cohort the optimal 
scan duration is 90 min. 
LOGAN 
Kinetic modelling suggested that 18F-GE180 has a reversible feature, therefore we applied 
Logan graphical analysis (19) to generate parametric maps. Based on linear fit of the whole 
brain and the appropriate weight for different time points, dynamic data from 20 to 90 min 
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(8 data points) were selected to generate Logan straight line (slope=0.147±0.06 and 
intercept=-1623±387) for parametric map (Fig.5). The Logan VT values (Supplementary 
file 4) were correlated with 2TCM4k VT values with a strong correlation in four cortices 
and hippocampus in both HABs (p<0.0001) and MABs (p<0.0001) (Fig. 6). The HABs 
showed generally higher Logan VT values than MABs; however, there were no statistically 
significant differences in this small sample. 
 
DISCUSSION 
This is the first study evaluating different approaches for PET modelling of the third 
generation TSPO tracer 18F-GE180 in older healthy subjects, establishing the optimum 
scanning time in this study population. There was consistently higher 18F-GE180 activity 
in plasma than in whole blood, but brain VT values generated from plasma input functions 
were low (around 0.16). Data were acquired for 210 min after injection of 18F-GE180 and 
five different kinetic models were evaluated in this study. The 18F-GE180 VT remained 
unchanged when the scan length was reduced to 90 min, but changes were observed when 
reducing the scan length to 75 min and 60 min, suggesting that 90 min might be the minimal 
scan time for 18F-GE180 PET. The 2TCM4k model demonstrated the lowest AIC and CV 
among the five kinetic models, suggesting that the 2TCM4k model could be the best model 
to estimate 18F-GE180 uptake. Compared to the 2TCM4k model, Logan graphical analysis 
allows us to create parametric maps and to estimate VT at voxel level.  Logan VT was highly 
correlated with 2TCM4k VT in all cortices, indicating that the Logan graphical analysis can 
be used to create unbiased parametric VT maps for 18F-GE180. 
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Consistent with a preclinical study (8), HPLC revealed three separate 18F-GE180   plasma 
metabolites, with a similar profile in HAB and MAB and no significant differences 
between HABs and MABs in plasma:blood ratios. The plasma:blood ratio for tracers 
crossing the BBB by passive diffusion is close to unity at the beginning of PET. 18F-GE180 
showed a relatively high plasma:blood ratio of 1.55, indicating higher concentration in 
plasma over red blood cells. A persistently high plasma:blood ratio throughout the scan 
reflects poor membrane penetration of 18F-GE180 across red cell membranes. In vitro 
assays of plasma protein binding of 18F-GE180 in human samples showed a relatively high 
percentage (97.4%) plasma protein binding, which was also seen with other TSPO tracers. 
 
Preclinical animal models showed that 18F-GE180 crosses the BBB readily. In humans, 
18F-GE180 demonstrated a relatively low VT in the brain, possibly due to: 1) low 
availability of the GE180 due to significant plasma protein binding, 2) low BBB 
permeability or 3) clearance by efflux pumps. Despite the fact that species differences have 
been observed in the BBB structure (20) and other novel brain PET tracers (21), the 
significant difference observed between human and preclinical models in 18F-GE180 could 
be primarily due to a significantly higher binding to plasma protein in humans.  
 
18F-GE180 preclinical studies demonstrated that, in rats, there is a clear regional 
differentiation of high TSPO expressing regions (olfactory bulbs) compared to low TSPO 
expressing regions (striatum) (22). In this study, five subjects (1 MAB and 4 HABs) 
revealed lowest uptake in striatum, three (MABs) showed lowest uptake in cerebellum, two 
(HABs) showed a more generalized distribution of TSPO expression. This inconsistent 
by Imperial College London Library on May 17, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
 15 
 
pattern suggests that a single predefined reference region for non-specific binding may not 
be appropriate for 18F-GE180 in humans in this age group.  
 
As TSPO expression is low in healthy brain, the 18F-GE180 VT values were relatively small 
in all ROI regions (range 0.15 to 0.20). A higher signal in thalamus compared to other 
regions was found, consistent with previous 11C-(R)-PK11195 studies (23). However, VT 
values of 18F-GE180 suggest that tracer brain uptake is relatively low compared to other 
TSPO PET radioligands, though the impact of this radioligand as a microglial imaging 
marker cannot be determined until we have results in specific disease conditions. The 
significant inverse correlation between the 18F-GE180 input function and the VT in brain 
suggests reflects the higher uptake to plasma proteins in humans compared to animal 
models. 
 
Interestingly, the significant inverse correlation between 18F-GE180 input function and VT 
in brain for each binding class separately, with a correlation coefficient > 0.9, indicates that 
whole brain VT can be almost entirely predicted by plasma levels within each binding class. 
Given that it was not possible to estimate plasma free fractions reliably, possibly because 
the fluctuations in estimated VT may be due to fluctuations in free fractions across subjects. 
Indeed, higher plasma protein binding would result in higher plasma counts and lower 
volume of distribution. This observation replicates similar observations in other TSPO 
tracers (13, 24). Identification of an optimal reference method would allow us to further 
refine the analysis methods without the arterial input.  
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Most 2nd generation TSPO tracers, such as 11C-PBR28 and 11C-PBR111, demonstrated an 
association with the TSPO genotype, revealing a 30% higher uptake in whole brain of 
HABs than MABs. In this study, there was a 30-40% higher uptake in HABs, reaching 
significance in thalamus, parahippocampus and cerebellum. Nevertheless, there was some 
overlap between subjects; moreover their numbers in the study were also small. Compared 
to some second generation TSPO tracers, 18F-GE180 may be less sensitive to the TSPO 
binding affinity status and may behave more like 11C-(R)-PK11195. One could argue, some 
of the variability seen in the MABs and HABs could be due to test-retest variability, which 
we are evaluating. The high correlation between Logan VT and 2TCM4k VT suggests that 
Logan parametric mapping could be used to generate pixel-wise parametric VT maps. As 
Logan generally underestimates the VT (25), there was no statistically significant difference 
between HAB and MAB, potentially due to the small numbers in this pilot study. 
Additionally, consistently with VT results, the Logan VT parametric maps demonstrated 
heterogeneous distribution of 18F-GE180 uptake in the HC. This heterogeneity was 
observed in both HAB and MAB subgroups and was consistent with 2TCM4k model.  
 
While one of the limitations of this study is the small sample size, this pilot study provides 
the first insight into the performance of 18F-GE180 in normal human brain and information 
about the parent plasma input function. Another limitation is the exclusion of the LAB 
from the study, and our laboratory is recruiting more participants to evaluate this tracer 
further. The low expression of TSPO in normal brain could be another limitation of this 
study evaluating only HC. However, these scans were performed with an arterial input 
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function and an extensive scanning time of 210 min, providing significant information 
about the tracer kinetics and modelling of this novel TSPO tracer for future use.    
CONCLUSION 
This pilot study provides preliminary brain uptake kinetics of the novel TSPO tracer 18F-
GE180 in HC. We have demonstrated for the first time that 18F-GE180 shows uptake into 
the brain of HC and that the tracer VT could be effectively modelled using a 2TCM4k and 
Logan graphical models to quantify the TSPO binding in human brain. The plasma:blood 
ratio and the rate of metabolism and input functions were not different between HAB and 
MAB subjects. We have also demonstrated that 90 min is the optimal scan duration, 
providing enough information to generate the precise and accurate estimates of VT. Semi-
quantitative SUV analysis for tracer uptake demonstrated a good correlation with kinetic 
modeling VT values. Logan graphical analysis with arterial input function enables us to 
generate 18F-GE180 parametric maps for voxel-wise analyses.  
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FIGURE 1. 18F-GE180 blood data: (A) HPLC analysis for 18F-GE180 at 15 min in a HAB 
subject (solid line) and a MAB subject (dashed line). (B) 18F-GE180 parent fraction in 
arterial plasma. (C) Plasma:blood ratio in HABs (circle) and MABs (square). (D) The SUV 
for parent plasma and whole blood as the group and the parent plasma input function curve 
in either HAB or MAB cohorts. 
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FIGURE 2. SUV corrected time-activity curves of 18F-GE180 in parietal, occipital lobe, 
thalamus and striatum for HABs (circle) and MABs (square).  
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FIGURE 3. Kinetic model selection (A) This figure represents the AIC values for five 
models in frontal lobe, temporal lobe, parietal lobe, occipital lobe and whole brain. (B) 
Graph with AIC fraction, revealing the frequency of AIC preferences for each model across 
all subjects. Frontal = Frontal lobe, Temporal = Temporal Lobe, Parietal = Parietal Lobe, 
Occipital = Occipital Lobe.  
  
by Imperial College London Library on May 17, 2017. For personal use only. jnm.snmjournals.org Downloaded from 
 25 
 
 
FIGURE 4. 18F-GE180 regional VT in 2TCM4k model. Regional volume of distribution 
with application of 2TCM4k model in twelve ROI regions. The circle with black bar 
represents the HABs while the square with white bar represents the MABs. 
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FIGURE 5. Individual 18F-GE180 Logan parametric maps in transverse view were 
demonstrated with its corresponding MRI.  
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FIGURE 6. Volume of distribution in two-tissue reversible model and Logan parametric 
map have demonstrated similar VT results with strong Pearson correlation in four cortices 
and hippocampus in both HABs (p<0.0001) and MABs (p<0.0001)  
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TABLE 1. Regional VT for 18F-GE180 applied 2TCM4k model in all healthy controls, HABs and MABs.  
18F-GE180 2TCM4K FL TL PL OL WB P-cing Thalamus Brainstem Striatum MTL Hippo CB 
All Subjects Mean 0.15 0.16 0.15 0.17 0.15 0.16 0.20 0.19 0.15 0.17 0.17 0.15 
 SD 0.06 0.07 0.05 0.06 0.06 0.06 0.09 0.09 0.06 0.06 0.08 0.07 
TSPO Genetic Subgroup               
HAB Mean 0.17 0.18 0.17 0.20 0.17 0.18 0.24 0.21 0.17 0.19 0.20 0.18 
 SD 0.06 0.07 0.05 0.06 0.07 0.06 0.09 0.09 0.05 0.07 0.08 0.07 
MAB Mean 0.12 0.13 0.12 0.14 0.12 0.12 0.14 0.16 0.10 0.13 0.13 0.11 
 SD 0.05 0.05 0.05 0.05 0.05 0.05 0.06 0.09 0.05 0.05 0.06 0.05 
HAB vs. MAB t test 0.11 0.09 0.12 0.06 0.11 0.07 0.04* 0.18 0.07 0.06 0.09 0.05* 
  Increase 39% 45% 36% 45% 40% 49% 73% 36% 64% 50% 51% 63% 
*p<0.05; FL = Frontal Lobe; TL = Temporal Lobe; PL = Parietal Lobe; OL = Occipital Lobe; WB = Whole Brain; P-cing = Posterior 
Cingulate; MTL = Medial Temporal Lobe; Hippo = Hippocampus; and CB = Cerebellum. 
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